Until recently, Herceptin, which is used to treat patients with metastatic breast cancer, was fully covered under Humana’s South Florida Medicare Advantage plans. But, after taking it off the preferred drug list, patients will now be responsible for 20 percent of the drug’s cost, better aligning South Florida’s plans with Humana’s other Medicare Advantage plans.
As costs decrease, and physicians move to address barriers to genetic testing, a panel of physicians, researchers and a patient advocate highlighted the importance for people to get tested.
It's challenging to accept the physical limitations one may experience post-cancer, but changes to the body can pose real physical constraints.
Treatments and surgeries are a personal choice. Patients should talk with doctors and other patients and survivors to determine what is best for them.
Clinical trials designed to evaluate the use of anti-cancer drugs for the treatment of cancer typically exclude patients whose disease has spread to the brain or CNS for a number of reasons, including the misperception that they are poor clinical trial candidates.
The scars breast cancer leaves on our bodies tell a story. What will yours say?
Today women face a plethora of options. Their tumors are tested for all kinds of differences that may tell them if chemotherapy will work and which drugs would work best. There are support groups and help for families that we didn’t have.
Breast cancer survivor gives ideas to cope with genetic cancer test results worry.
The oldest cases of multiple myeloma and breast cancer date back to ancient Egyptian mummies.
When we are in situations in which others will see our cancer scars, do we have to explain them or worry about what someone else thinks?
Breast cancer survivor tries to make rational choices based on newer genetic testing results.
A recurrence is always a possibility for any victim of cancer, but should survivors expect a recurrence? If so, how can they prepare for that possibility?
As a cancer survivor, reading some information brings an uneasy feeling.
Lynparza (olaparib) was granted approval by the Food and Drug Administration (FDA) for the treatment of patients with BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy. Also, patients who have HR-positive disease should have prior endocrine therapy or they would not be considered appropriate for such treatment.
"Garden variety" breast cancer is no longer the norm thanks to the discovery of more genetic mutations.
Those of us who had chemotherapy and/or radiation as part of our treatment have now been hit with another lovely late effect, if the results of a new study are accurate. We have the potential to age prematurely.
